Literature DB >> 6338907

Enolase isoenzymes in uveal melanomas--a possible parameter of malignancy.

J A Royds, I G Rennie, M A Parsons, W R Timperley, C B Taylor.   

Abstract

Seven uveal melanomas were stained for gamma enolase by an immunoperoxidase PAP (peroxidase-antiperoxidase) technique, and biochemical assays were carried out on tissue homogenates. A correlation between the biochemical assay and the immunoperoxidase staining was demonstrated. Two tumours with the highest biochemical assays showed positive staining for the enzyme, and 2 tumours with the lowest levels showed no appreciable staining. The highest level of enolase was present in a tumour which both clinically and histologically appeared to be benign, and the lowest level occurred in a mixed cell tumour which was large in size; the low level presumably related to its relatively fast rate of growth. Estimation of gamma enolase activity in ocular melanomas may provide an accurate quantitative method for assessing the malignant potential of these tumours.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338907      PMCID: PMC1040027          DOI: 10.1136/bjo.67.4.244

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells.

Authors:  D Schmechel; P J Marangos; M Brightman
Journal:  Nature       Date:  1978 Dec 21-28       Impact factor: 49.962

2.  Enolase isoenzymes in rat tissues. Electrophoretic, chromatographic, immunological and kinetic properties.

Authors:  C C Rider; C B Taylor
Journal:  Biochim Biophys Acta       Date:  1974-09-13

3.  Problems in the differential diagnosis of choroidal nevi and malignant melanomas. The XXXIII Edward Jackson Memorial Lecture.

Authors:  J D Gass
Journal:  Am J Ophthalmol       Date:  1977-03       Impact factor: 5.258

4.  [The migration of pigmentary cells studies by the method of heterospecific grafts of neural tube in bird embryo].

Authors:  M A Teillet; N Le Douarin
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1970-06-22

5.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

6.  Neurons switch from non-neuronal enolase to neuron-specific enolase during differentiation.

Authors:  D E Schmechel; M W Brightman; P J Marangos
Journal:  Brain Res       Date:  1980-05-19       Impact factor: 3.252

7.  Brain endolases as specific markers of neuronal and glial cells.

Authors:  D Schmechel; P J Marangos; A P Zis; M Brightman; F K Goodwin
Journal:  Science       Date:  1978-01-20       Impact factor: 47.728

8.  Enolase isoenzymes. III. Chromatographic and immunological characteristics of rat brain enolase.

Authors:  L Fletcher; C C Rider; C B Taylor
Journal:  Biochim Biophys Acta       Date:  1976-11-08

9.  Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body.

Authors:  I W McLean; L E Zimmerman; R M Evans
Journal:  Am J Ophthalmol       Date:  1978-10       Impact factor: 5.258

10.  Neuronal, non-neuronal and hybrid forms of enolase in brain: structural, immunological and functional comparisons.

Authors:  P J Marangos; A P Zis; R L Clark; F K Goodwin
Journal:  Brain Res       Date:  1978-07-07       Impact factor: 3.252

View more
  3 in total

1.  Gamma-enolase activity in choroidal melanoma.

Authors:  C E Margo; M Lavellée
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

2.  Electrophoretic assessment of aqueous and serum neurone-specific enolase in retinoblastoma and ocular malignant melanoma.

Authors:  B S Shine; J Hungerford; B Vaghela; G A Sheraidah
Journal:  Br J Ophthalmol       Date:  1990-07       Impact factor: 4.638

3.  Prognosis of conjunctival melanomas in relation to histopathological features.

Authors:  U Fuchs; T Kivelä; K Liesto; A Tarkkanen
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.